GHK-Cu Goes to Committee: Why the Copper Peptide's February 2027 Review Matters

Sometime before the end of February 2027, a federal advisory committee will vote on whether copper peptide can be used by compounding pharmacies.

This is an unusual situation. GHK-Cu is not an obscure research compound. It is an ingredient sold at scale in retail skincare, sitting in bathroom cabinets in serums that cost anywhere from twelve dollars to several hundred. It is also, simultaneously, a substance under active federal regulatory review.

Both things are true, and they are true for different forms of the same molecule.

What GHK-Cu is

GHK is a naturally occurring tripeptide — glycyl-L-histidyl-L-lysine — that binds copper ions to form a stable complex. It is present in human plasma, and plasma levels decline substantially with age, which is the observation that launched most of the commercial interest.

Research attention has centered on wound repair, extracellular matrix signaling and collagen-related activity. Much of the underlying work is decades old, and much of it is laboratory or animal work rather than controlled human trials.

The route split, and why it decides everything

Here is the part that gets flattened in nearly every article written about this.

Same tripeptide. Three different regulatory realities, separated by how it enters the body and what it is sold as.

The February 2027 review concerns injectable GHK-Cu. Your serum is not the subject of that meeting, is not affected by its outcome, and was never in question.

Why this review is the one to watch

The July 2026 meeting covered compounds most people had never heard of before the headlines: KPV, MOTS-c, Epitalon. Their consumer footprint was small.

GHK-Cu is different. It has a mass-market cosmetic presence, a large and mostly female consumer base, and a decade of marketing that has trained people to think of it as a proven anti-aging ingredient. When a federal committee votes on it, that vote will be reported — and it will be reported badly.

The specific misreading to expect

A recommendation on injectable GHK-Cu will be marketed as validation of topical copper peptide products. It will not be. The committee will be answering whether an injectable preparation can be adequately characterized and safely compounded in a pharmacy. That question has no bearing on whether a cosmetic serum does anything for your skin.

Conversely, if the committee declines to recommend it, expect the reverse distortion — competitors framing a compounding decision as a finding that copper peptides do not work. That would be equally wrong.

What July suggests about February

The July meeting produced a usable pattern, though not a reliable prediction.

FDA scientists recommended against all seven nominations, citing insufficient safety data, insufficient efficacy data and inadequate characterization. The committee overrode them six times out of seven, on margins no wider than three votes.

The compound that failed — emideltide — came in carrying three separate indications across addiction medicine and two sleep disorders. Narrowly scoped nominations fared better than broad ones, independent of the underlying science.

If that pattern holds, how the GHK-Cu nomination is framed may matter as much as the evidence behind it.

The other four on the February slate

GHK-Cu is not alone. The committee will also consider:

• Cathelicidin LL-37 — an antimicrobial peptide in innate immune defense. The FDA has previously flagged limited human safety information, potential immunogenicity, reproductive findings in nonclinical research, and the possibility of tumor-promoting activity in certain tissues. That is the most serious concern set on the slate.
• Melanotan II — the tanning peptide, and the one with a documented consumer-harm record. We cover it separately.
• Dihexa acetate — an angiotensin IV analog studied for neurotrophic activity, with essentially no human data.
• PEG-MGF — pegylated mechano growth factor, associated with muscle repair research and banned in competitive sport.

What to do with this before February

Practically, very little changes between now and then. But two things are worth holding onto.

First, if you use a topical copper peptide product, nothing about this review touches it. Cosmetic regulation is a separate system, and a vote on injectables will not make your serum better or worse than it was.

Second, when the vote lands, the quality of a source will be visible immediately in whether it distinguishes injectable from topical. That single distinction is the tell.